Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Grant of Options

1 Jul 2024 07:00

RNS Number : 4662U
Cambridge Cognition Holdings PLC
01 July 2024
 

1 July 2024

 

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Grant of Options

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that on 28 June 2024, the Company granted options (the "Options") over a total of 903,574 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") pursuant to the Company's 2022 Long Term Incentive Plan ("LTIP").

 

The Options include:

 

1. Options over 354,421 Ordinary Shares granted to Persons Discharging Managerial Responsibilities ("PDMRs") as follows:

 

Name

Role

Number of Ordinary Shares over which Options Granted

Total number of Ordinary Shares over which Options held following Grant

Total number of Ordinary Shares held

Percentage of Current Issued Share Capital Held

Matthew Stork

Chief Executive Officer

192,307

1,332,504

223,950

0.54%

Alex Livingstone- Learmonth

Chief Commercial Officer

115,384

115,384

10,000

0.02%

Ricky Dolphin

Chief Technology Officer

46,730

311,589

120,584

0.29%

 

2. Options over 549,153 Ordinary Shares granted to other employees of the Company.

The Options granted to the PDMRs are in each case "performance share awards" that are exercisable at a price of 1 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to continued service and to the extent to which challenging performance conditions are achieved.

 

Under the terms of the aforementioned performance conditions, one-half of each of the Options is subject to sliding scale compound annual growth rate targets for adjusted revenue over the three year period ending 31 December 2026, the other half of each of the Options is subject to a sliding scale measure of relative total shareholder performance over a three year period that commenced on the grant of the Options.

 

The Options granted to other employees of the Company (save for one more performance share award) are exercisable at a price of 1 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, and will vest subject to continued service (so called 'restricted share awards').

 

The LTIP has scope to grant both EMI awards and non-EMI awards and was recently adopted by the Board. The terms of the LTIP align to best practice expectations, including leaver terms and malus and clawback provisions.

 

Following the grant of Options, the total number of options outstanding over unissued Ordinary Shares is 3,383,747 representing approximately 8.22% of the Company's issued share capital.

 

Enquiries

 

Cambridge Cognition Holdings plc

Matthew Stork, Chief Executive Officer

Stephen Symonds, Chief Financial Officer

Tel: 01223 810 700

press@camcog.com

Panmure Liberum Limited (NOMAD and Joint Broker)

Tel: 020 78862500

Freddy Crossley / Emma Earl / Mark Rogers

(Corporate Advisory)

Rupert Dearden

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney/ James Serjeant

Tel: 020 3903 7715

(Corporate Broking)

Hudson Sandler (Financial PR and IR)

Tel: 020 7796 4133

Dan de Belder/Hattie Dreyfus

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Names

Matthew Stork - Chief Executive Officer

Alex Livingstone - Learmonth - Chief Commercial Officer

Ricky Dolphin - Chief Technology Officer

2. 

Reason for the Notification

a)

Position/status

See 1(a) above for positions - all classified as PDMRs of the Company

b)

Initial notification/ Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings plc

b)

LEI

213800SZKDIN122EPA96

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

In each case, the grant of Options over Ordinary Shares on 28 June 2024

 

Identification code

GB00B8DV9647

b)

Nature of the transaction

Grant of Options over Ordinary Shares each with an exercise price of 1 pence per Ordinary Share

 

c)

Price(s) and volume(s)

Price: n/a

Volumes:

Matthew Stork - Options over 192,307 Ordinary Shares

Alex Livingstone-Learmonth - Options over 115,384 Ordinary Shares

Ricky Dolphin - Options over 46,730 Ordinary Shares

d)

Aggregated information:

· Aggregated volume

· Price

 

354,421n/a

e)

Date of the transaction

28 June 2024

f)

Place of the transaction

Outside a trading venue

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company marketing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKVLFLZQLBBBD
Date   Source Headline
1st Jun 20267:00 amRNS-RCOG to present at Mello 2026
28th May 20261:15 pmRNSLaunch of brain health study with Oura
21st May 20262:50 pmRNSResult of AGM
24th Apr 20263:16 pmRNSPosting of Annual Report & Notice of AGM
13th Apr 20267:00 amRNSResults for the year ended 31 December 2025
7th Apr 20267:01 amRNSNotice of Results
7th Apr 20267:00 amRNSAppointment of Nominated Adviser and Joint Broker
1st Apr 20267:00 amRNSBlock Listing Return
11th Mar 20267:00 amRNSMonument Therapeutics MT1988 First Patient Dosed
11th Mar 20267:00 amRNSMonument Therapeutics MT1988 First Patient Dosed
16th Feb 20267:00 amRNSCommercialisation Agreement
9th Feb 20267:00 amRNSChange of Joint Broker
19th Jan 20267:00 amRNSTrading Update
5th Nov 20257:01 amRNSChange of Auditor
5th Nov 20257:00 amRNSBoard Updates
1st Oct 20257:00 amRNSBlock Listing Return
29th Sep 20257:00 amRNSExercise of Options and Total Voting Rights
26th Sep 20259:59 amRNSHolding(s) in Company
8th Sep 20257:00 amRNSHolding(s) in Company
5th Sep 20252:51 pmRNSHolding(s) in Company
5th Sep 202512:04 pmRNSHolding(s) in Company
2nd Sep 20255:21 pmRNSHolding(s) in Company
1st Sep 202510:58 amRNS-RInvestor Presentation via Investor Meet Company
28th Aug 202510:45 amRNS£1.12m Placing & Subscription, TVR & PDMR Dealings
28th Aug 20257:01 amRNSChanges to Board and Management
28th Aug 20257:00 amRNSInterim Results
19th Aug 202510:10 amRNS-RMonument Therapeutics Partnership with FNIH
12th Aug 20257:00 amRNSLaunch of Speaker Identification Solution
31st Jul 20257:00 amRNSTrading update for period ended 30 June 2025
27th Jun 202512:27 pmRNSResult of AGM
24th Jun 20257:00 amRNS-RMonument Therapeutics Success in Phase I Results
4th Jun 20257:00 amRNSNotice of AGM
6th May 20255:59 pmRNSHolding(s) in Company
1st May 20257:00 amRNSPreliminary Unaudited Results
24th Apr 20257:00 amRNSNotice of Results and Investor Presentation
10th Apr 20257:00 amRNSContract Win
7th Apr 202510:24 amRNSHolding(s) in Company
3rd Apr 20257:00 amRNSContract Win
1st Apr 20257:00 amRNSBlock Listing Return
6th Mar 20257:00 amRNS-RCANTAB® used for major global brain health study
18th Feb 20257:00 amRNS-RCambridge Cognition submits FDA Letter of Intent
7th Feb 20257:00 amRNSBoard Appointment
21st Jan 20257:00 amRNSLaunch of in-house rater training service
16th Jan 20257:00 amRNSExpanded partnership with Actinogen
27th Dec 20243:34 pmRNSDirector/PDMR Share Purchases
23rd Dec 20244:02 pmRNSDirector/PDMR Share Purchases
16th Dec 20249:20 amRNSDirector/PDMR Share Purchases
10th Dec 20247:00 amRNSTrading Update
18th Nov 20244:02 pmRNSHolding(s) in Company
6th Nov 20247:00 amRNSMonument Therapeutics secures £1m investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.